Published in J Clin Oncol on May 24, 2010
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med (2011) 4.47
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
Self-renewal as a therapeutic target in human colorectal cancer. Nat Med (2013) 4.20
An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol (2014) 2.45
HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res (2013) 2.27
A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res (2011) 2.26
Metformin: multi-faceted protection against cancer. Oncotarget (2011) 2.00
Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin Cancer Res (2011) 1.91
Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL. Breast Cancer Res (2011) 1.54
Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells. Clin Cancer Res (2011) 1.54
Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer (2011) 1.53
Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol (2012) 1.50
MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet (2012) 1.38
Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology (2014) 1.35
Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal (2013) 1.24
Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival. Endocr Relat Cancer (2011) 1.23
Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer. Breast Cancer Res (2012) 1.21
Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment. Cell Death Dis (2014) 1.20
The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell Cycle (2013) 1.20
Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle (2012) 1.18
Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med (2011) 1.17
Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells. Oncogene (2011) 1.17
The role of breast cancer stem cells in metastasis and therapeutic implications. Am J Pathol (2011) 1.16
Wnt/catenin signaling in adult stem cell physiology and disease. Stem Cell Rev (2014) 1.15
Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis. Mol Med (2012) 1.15
Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. Br J Cancer (2011) 1.09
Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells. Endocr Relat Cancer (2013) 1.06
Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells. Cell Death Differ (2012) 1.05
ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer. Proc Natl Acad Sci U S A (2012) 1.04
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PLoS One (2011) 1.03
Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. Cancer Res (2013) 1.03
Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. BMC Med Genomics (2011) 1.02
Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance. Curr Pharm Des (2015) 1.01
Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat (2011) 1.01
DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression. Nat Commun (2015) 1.00
Notch signaling in prostate cancer: a moving target. Prostate (2014) 0.98
Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle (2012) 0.95
Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations. PLoS One (2011) 0.93
EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer. Cell Cycle (2013) 0.93
MicroRNA100 inhibits self-renewal of breast cancer stem-like cells and breast tumor development. Cancer Res (2014) 0.93
Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer. Oncotarget (2015) 0.93
Loss of CLCA4 promotes epithelial-to-mesenchymal transition in breast cancer cells. PLoS One (2013) 0.92
Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy. Sci Rep (2012) 0.92
Nodal expression and detection in cancer: experience and challenges. Cancer Res (2012) 0.92
Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell. Oncotarget (2014) 0.91
Regulation of cancer stem cell activities by tumor-associated macrophages. Am J Cancer Res (2012) 0.90
Cisplatin and TRAIL enhance breast cancer stem cell death. Int J Oncol (2011) 0.90
Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1. Cancer Med (2013) 0.90
Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer. Cancer Res (2014) 0.89
A mammosphere formation RNAi screen reveals that ATG4A promotes a breast cancer stem-like phenotype. Breast Cancer Res (2013) 0.89
RKIP-mediated chemo-immunosensitization of resistant cancer cells via disruption of the NF-κB/Snail/YY1/RKIP resistance-driver loop. Crit Rev Oncog (2014) 0.88
The Rab2A GTPase promotes breast cancer stem cells and tumorigenesis via Erk signaling activation. Cell Rep (2015) 0.88
Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society. J Cancer Res Clin Oncol (2013) 0.87
MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway. Cancer Sci (2015) 0.87
CD147-dependent heterogeneity in malignant and chemoresistant properties of cancer cells. Am J Pathol (2012) 0.87
Peroxisome proliferator activated receptor-α/hypoxia inducible factor-1α interplay sustains carbonic anhydrase IX and apoliprotein E expression in breast cancer stem cells. PLoS One (2013) 0.86
Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6-Abundant Breast Cancer Cells by Regulating γ-Secretase-Mediated Notch1 Activation in Caveolae. Neoplasia (2015) 0.83
Cyclohexylmethyl Flavonoids Suppress Propagation of Breast Cancer Stem Cells via Downregulation of NANOG. Evid Based Complement Alternat Med (2013) 0.83
The role of non-coding RNAs in the regulation of stem cells and progenitors in the normal mammary gland and in breast tumors. Front Genet (2015) 0.83
Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor. Nat Commun (2015) 0.83
Modeling of Cancer Stem Cell State Transitions Predicts Therapeutic Response. PLoS One (2015) 0.82
The role of radiotherapy-resistant stem cells in breast cancer recurrence. Breast Cancer Manag (2015) 0.82
Biological and clinical significance of cancer stem cell plasticity. Clin Transl Med (2014) 0.82
Using SV119-gold nanocage conjugates to eradicate cancer stem cells through a combination of photothermal and chemo therapies. Adv Healthc Mater (2014) 0.81
Bioengineering embryonic stem cell microenvironments for the study of breast cancer. Int J Mol Sci (2011) 0.81
Combining Notch inhibition with current therapies for breast cancer treatment. Ther Adv Med Oncol (2013) 0.81
Can CD44+/CD24- Tumor Cells Be Used to Determine the Extent of Breast Cancer Invasion Following Neoadjuvant Chemotherapy? J Breast Cancer (2011) 0.81
Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer. Oncotarget (2016) 0.80
Induction of caspase-dependent extrinsic apoptosis by apigenin through inhibition of signal transducer and activator of transcription 3 (STAT3) signalling in HER2-overexpressing BT-474 breast cancer cells. Biosci Rep (2015) 0.80
Investigating breast cancer cell behavior using tissue engineering scaffolds. PLoS One (2015) 0.79
In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors. BMC Cancer (2015) 0.79
Targeting breast cancer stem cells: fishing season open! Breast Cancer Res (2010) 0.79
Increased Expression of Beige/Brown Adipose Markers from Host and Breast Cancer Cells Influence Xenograft Formation in Mice. Mol Cancer Res (2015) 0.79
Tumor senescence and radioresistant tumor-initiating cells (TICs): let sleeping dogs lie! Breast Cancer Res (2010) 0.78
Decoding the usefulness of non-coding RNAs as breast cancer markers. J Transl Med (2016) 0.78
URGCP/URG4 promotes apoptotic resistance in bladder cancer cells by activating NF-κB signaling. Oncotarget (2015) 0.78
Breast cancer stem-like cells: clinical implications and therapeutic strategies. Clujul Med (2016) 0.78
Unsupervised deconvolution of dynamic imaging reveals intratumor vascular heterogeneity and repopulation dynamics. PLoS One (2014) 0.77
Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis. Mol Cancer Res (2015) 0.77
Smad2/3-Regulated Expression of DLX2 Is Associated with Radiation-Induced Epithelial-Mesenchymal Transition and Radioresistance of A549 and MDA-MB-231 Human Cancer Cell Lines. PLoS One (2016) 0.77
Inhibition of FAK kinase activity preferentially targets cancer stem cells. Oncotarget (2017) 0.76
Low-dose radiation decreases tumor progression via the inhibition of the JAK1/STAT3 signaling axis in breast cancer cell lines. Sci Rep (2017) 0.75
Loss-of-function screens of druggable targetome against cancer stem-like cells. FASEB J (2016) 0.75
Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers. EMBO Mol Med (2017) 0.75
Cryoablation and Meriva have strong therapeutic effect on triple-negative breast cancer. Oncoimmunology (2015) 0.75
AKR1B1 promotes basal-like breast cancer progression by a positive feedback loop that activates the EMT program. J Exp Med (2017) 0.75
Autocrine interleukin-23 promotes self-renewal of CD133+ ovarian cancer stem-like cells. Oncotarget (2016) 0.75
Clinical trial design for testing the stem cell model for the prevention and treatment of cancer. Cancers (Basel) (2011) 0.75
Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer. EBioMedicine (2016) 0.75
Targeting cancer stem cells with ALDH1A1-based immunotherapy. Oncoimmunology (2012) 0.75
A role of TGFß1 dependent 14-3-3σ phosphorylation at Ser69 and Ser74 in the regulation of gene transcription, stemness and radioresistance. PLoS One (2013) 0.75
Determining duration of HER2-targeted therapy using stem cell extinction models. PLoS One (2012) 0.75
Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer. PLoS One (2012) 0.75
Microfluidics 3D gel-island chip for single cell isolation and lineage-dependent drug responses study. Lab Chip (2016) 0.75
Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers. Front Oncol (2017) 0.75
Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells. PLoS One (2017) 0.75
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev (2003) 20.77
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53
Generation of a functional mammary gland from a single stem cell. Nature (2006) 18.30
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med (2005) 16.70
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res (2009) 7.98
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A (2007) 4.97
Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer (2003) 4.86
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest (2007) 4.71
HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene (2008) 4.53
Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst (2006) 4.47
Requirement for beta-catenin in anterior-posterior axis formation in mice. J Cell Biol (2000) 4.36
The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer (2007) 4.01
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res (2008) 3.98
Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci (2004) 3.85
Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol (2009) 3.67
Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol (2009) 3.58
C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol (2007) 3.42
Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A (2009) 3.13
Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab (2004) 3.10
Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res (2005) 3.05
HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med (2008) 3.05
Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res (2009) 2.49
The Wnt co-receptors Lrp5 and Lrp6 are essential for gastrulation in mice. Development (2004) 2.45
Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res (2000) 2.22
Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res (2009) 2.14
Notch4 and Wnt-1 proteins function to regulate branching morphogenesis of mammary epithelial cells in an opposing fashion. Dev Biol (1998) 1.90
Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A (2008) 1.76
Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs (2007) 1.76
Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett (2009) 1.75
p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells (2006) 1.72
DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res (2009) 1.67
MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res (2008) 1.66
The paradox of response and survival in cancer therapeutics. Blood (2005) 1.63
HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res (2009) 1.59
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol (2008) 1.58
Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle (2005) 1.54
Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol (2003) 1.36
NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia (2009) 1.27
Expression of an activated Notch4(int-3) oncoprotein disrupts morphogenesis and induces an invasive phenotype in mammary epithelial cells in vitro. Int J Cancer (2000) 1.23
The patched/hedgehog/smoothened signalling pathway in human breast cancer: no evidence for H133Y SHH, PTCH and SMO mutations. Eur J Cancer (1999) 1.18
Treatment resistance in stem cells and breast cancer. J Mammary Gland Biol Neoplasia (2009) 1.10
C-reactive protein, inflammation, and cardiovascular disease: clinical update. Tex Heart Inst J (2005) 1.07
Expanding the arsenal: metformin for the treatment of triple-negative breast cancer? Cell Cycle (2009) 0.93
Targeted therapies in multiple myeloma. Target Oncol (2009) 0.84
Role of aldehyde dehydrogenase (ALDH) in the detoxication of cyclophosphamide (CP) in rat embryos. Adv Exp Med Biol (1991) 0.79
The role of interleukin-6 in inhibition of lung metastasis in subcutaneous tumor-bearing mice. Oncol Rep (2000) 0.78
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev (2003) 20.77
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res (2009) 7.98
Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res (2006) 7.91
Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res (2009) 6.43
Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res (2004) 5.60
BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A (2008) 4.79
Stem cells in normal breast development and breast cancer. Cell Prolif (2003) 4.47
Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res (2009) 4.47
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest (2010) 4.22
Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol (2009) 3.67
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A (2012) 3.21
Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res (2011) 3.18
Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab (2004) 3.10
Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res (2005) 3.05
Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol (2008) 2.87
Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck (2010) 2.76
Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest (2011) 2.62
Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res (2011) 2.50
Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell (2012) 2.34
HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res (2013) 2.27
Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia. J Mammary Gland Biol Neoplasia (2005) 2.13
Cancer stem cells: a step toward the cure. J Clin Oncol (2008) 2.08
Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer (2011) 2.05
Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res (2009) 2.04
Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res (2010) 1.96
Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol (2013) 1.92
Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin Cancer Res (2011) 1.91
Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res (2010) 1.88
Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res (2006) 1.84
Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol (2011) 1.79
Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat (2009) 1.77
Cancer stem cells in breast: current opinion and future challenges. Pathobiology (2008) 1.77
Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs (2007) 1.76
Targeting breast cancer stem cells. Mol Oncol (2010) 1.72
Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev (2005) 1.65
HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res (2009) 1.59
Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle (2009) 1.56
HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res (2012) 1.47
Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res (2013) 1.43
Point: cancer stem cells--the evidence accumulates. Clin Chem (2012) 1.43
Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res (2012) 1.39
An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma. Clin Cancer Res (2009) 1.38
MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet (2012) 1.38
Role of microRNAs in the regulation of breast cancer stem cells. J Mammary Gland Biol Neoplasia (2012) 1.25
Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res (2013) 1.20
Ablation of breast cancer stem cells with radiation. Transl Oncol (2011) 1.15
HER2 and breast cancer stem cells: more than meets the eye. Cancer Res (2013) 1.14
Mammary stem cell number as a determinate of breast cancer risk. Breast Cancer Res (2007) 1.12
Colon cancer stem cells: implications for prevention and therapy. Trends Mol Med (2008) 1.12
Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem (2011) 1.10
Distinct FAK activities determine progenitor and mammary stem cell characteristics. Cancer Res (2013) 1.04
Cancer stem cells: implications for cancer treatment and prevention. Cancer J (2007) 1.04
Cancer stem cell heterogeneity in hereditary breast cancer. Breast Cancer Res (2008) 1.04
Stem cells in normal development and cancer. Prog Mol Biol Transl Sci (2010) 0.98
Getting to the root of BRCA1-deficient breast cancer. Cell Stem Cell (2009) 0.95
Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol (2013) 0.95
Endothelial interleukin-6 defines the tumorigenic potential of primary human cancer stem cells. Stem Cells (2014) 0.93
Cancer stem cells: nature versus nurture. Nat Cell Biol (2010) 0.92
New organizational and funds flow models for an academic cancer center. Acad Med (2004) 0.91
Regulatory roles of miRNA in the human neural stem cell transformation to glioma stem cells. J Cell Biochem (2014) 0.91
Breast cancer stem cells: we've got them surrounded. Clin Cancer Res (2012) 0.90
Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell activity. Mol Cancer Ther (2015) 0.89
Breast cancer stem cells-research opportunities utilizing mathematical modeling. Stem Cell Rev (2007) 0.88
A radial flow microfluidic device for ultra-high-throughput affinity-based isolation of circulating tumor cells. Small (2014) 0.88
Lin28 and HER2: two stem cell regulators conspire to drive aggressive breast cancer. Cell Cycle (2012) 0.86
[The cancer stem cell: the breast cancer driver]. Med Sci (Paris) (2007) 0.85
CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res Treat (2015) 0.84
Inflammation and autophagy conspire to promote tumor growth. Cell Cycle (2011) 0.84
Breast cancer stem cells: current advances and clinical implications. Methods Mol Biol (2015) 0.83
Targeting cancer stem cells via dendritic-cell vaccination. Oncoimmunology (2012) 0.82
Identification of single chain antibodies to breast cancer stem cells using phage display. Biotechnol Prog (2009) 0.82
Stemming a tumor with a little miR. Nat Med (2011) 0.81
The thyroid cancer PAX8-PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype. Endocr Relat Cancer (2013) 0.81
[Stem cells and epithelial cancers: the example of breast cancer]. Ann Pathol (2008) 0.78
Migratory gene expression signature predicts poor patient outcome: are cancer stem cells to blame? Breast Cancer Res (2012) 0.78
KRAS and cancer stem cells in APC-mutant colorectal cancer. J Natl Cancer Inst (2014) 0.77
Antiangiogenic agents: fueling cancer's hypoxic roots. Cell Cycle (2012) 0.77
Generation of a novel dendritic-cell vaccine using melanoma and squamous cancer stem cells. J Vis Exp (2014) 0.77
Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer. Breast Cancer Res (2009) 0.76
Clinical trial design for testing the stem cell model for the prevention and treatment of cancer. Cancers (Basel) (2011) 0.75
Breast tumors: of mice and women. Breast Cancer Res (2010) 0.75
Single cell dual adherent-suspension co-culture micro-environment for studying tumor-stromal interactions with functionally selected cancer stem-like cells. Lab Chip (2016) 0.75
Tumor-initiating cells and treatment resistance: how goes the war? J Mammary Gland Biol Neoplasia (2009) 0.75